Dong Ju Kim

Dong Ju Kim

Auto-generated profile, based on publicly available information

Dong Ju Kim

Department of Ophthalmology, Seoul National University College of Medicine, Seoul, Republic of Korea

Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
31 January 2023 in Ophthalmologica
Verified
Journal Article
Closed access
PDF file
DKDong Ju Kim
Dong Ju Kim
KJKi Won Jin
Ki Won Jin
JHJeong Mo Han
Jeong Mo Han
SLSeung Hyun Lee
Seung Hyun Lee
YPYong Seok Park
Yong Seok Park
Se Joon WooSe Joon Woo
Se Joon Woo
Introduction: The aim of the study was to determine the short-term real-world safety and efficacy of intravitreal brolucizumab injections in Korean patients with neovascular age-related macular degeneration (nAMD). Methods: This multicenter retrospective study involved 294 eyes (treatment naïve 20 eye [6.8%] and nontreatment naïve 274 eyes [93.2%]) of 290 patients from 13 hospitals or retinal centers in South Korea. Patients with nAMD who received brolucizumab injection(s) between April 1 and November 30, 2021, with a follow-up ≥1 month, were included. Primary outcomes were safety, incidence of intraocular inflammation (IOI), and potential risk factors. The secondary outcome was efficacy, i.e., change in best-corrected visual acuity (BCVA) and optical coherence tomography-measured macular thickness and retinal fluid. Results: The mean age was 71.63 ± 8.66. The follow-up period was 2.38 ± 0.79 months. The mean number of brolucizumab injections during the follow-up was 1.52 ± 0.58. The overall incidence of IOI was 13.9% (n = 41 eyes). Most IOI cases were of anterior uveitis (8.8%, 26 eyes), followed by retinal vasculitis (2.4%, seven eyes) and occlusive retinal vasculitis (0.3%, one eye). Most eyes showed IOI resolution (n = 40, 97.5%) and BCVA restoration (n = 39, 95.1%) with or without corticosteroid treatment during the follow-up. Age, sex, IOI history, or other anti-vascular endothelial growth factor injection histories were not associated with the occurrence of IOI. However, only thin subfoveal choroidal thickness (SFCT) was associated with the occurrence of IOI (odds ratio = 0.995, p = 0.020). BCVA at 1 month improved from baseline (baseline 0.518 ± 0.356 vs. 1 month 0.503 ± 0.383, p = 0.023), but the improvement was not maintained. Anatomical improvement was significant after 3 months. Conclusion: In Korean patients with nAMD, the incidence of IOI following brolucizumab injections was 13.9%. IOI was well-controlled with or without steroid treatment. Most IOI eyes (95.1%) were restored to the level of vision before. IOI occurrence and occlusive vasculitis was rare. In the short term, brolucizumab injection effectively improved vision at 1 month and dried retinal fluid for 3 months.

5 May 2024 in Acta Ophthalmologica
Verified
Journal Article
Closed access
DKDong Ju Kim
Dong Ju Kim
DKDong geun Kim
Dong geun Kim
HKHyun Duck Kwak
Hyun Duck Kwak
JJJae Yong Jang
Jae Yong Jang
YJYong-Sok Ji
Yong-Sok Ji
Se Joon WooSe Joon Woo
Se Joon Woo

3 April 2025 in Ophthalmology Science
Verified
Journal Article
Open access
DKDong geun Kim
Dong geun Kim
SBSeok Hyun Bae
Seok Hyun Bae
DKDong Ju Kim
Dong Ju Kim
JLJong Suk Lee
Jong Suk Lee
KJKwangsic Joo
Kwangsic Joo
KPKyu Hyung Park
Kyu Hyung Park
To investigate and compare the clinical characteristics of patients with unilateral high myopia (UHM) and bilateral high myopia (BHM) based on axial length (AL). A retrospective cohort study. Adult patients diagnosed with UHM or BHM between March 2011 and August 2021. Unilateral high myopia was defined as ≥26 mm AL in 1 eye and <26 mm in the other, with ≥2 mm difference. Bilateral high myopia was defined as ≥26 mm AL in both eyes, with ≤3 mm difference. In each patient, the eye with the longer AL was designated the “longer eye” and the other the “shorter eye.” We analyzed differences in clinical features, including ophthalmic history, best-corrected visual acuity, ocular biometry, and myopic maculopathy grade. Myopic maculopathy was graded based on atrophy, traction, and neovascularization using a known method. Long-term features included treatments for myopic neovascular maculopathy and myopic tractional maculopathy and AL change over time. Comparison of clinical characteristics between UHM and BHM groups. We analyzed 369 patients (79 with UHM and 290 with BHM) with a median follow-up period of 4.5 years. The UHM group had a higher proportion of women than the BHM group (88.8% vs. 76.2%, P = 0.025). Compared with longer eyes in the BHM group, those in the UHM group had worse best-corrected visual acuity (0.8 ± 0.6 vs. 0.6 ± 0.6 in logarithm of the minimum angle of resolution, P < 0.001) despite having shorter AL (29.1 ± 1.6 mm vs. 30.6 ± 1.9 mm, P < 0.001). In the analysis of AL changes, shorter eyes in the UHM group showed no elongation over time (0.014 mm/year, P = 0.12), unlike the longer eyes in UHM and both eyes in BHM (0.049–0.071 mm/year, P < 0.01). Adult UHM patients mostly lacked associated environmental factors. The poorer visual acuity in the longer eyes of UHM patients, which cannot be explained by structural abnormalities, suggests that the interocular difference may have originated in early childhood. During the follow-up period, AL elongation and myopic complications occurred at similar rates in the longer eye of UHM and both eyes of BHM. Meanwhile, such changes were not observed in the shorter eye in UHM. Further investigation of the underlying mechanisms, such as the genetic factors contributing to this extreme asymmetry, is warranted. The author(s) have no proprietary or commercial interest in any materials discussed in this article.